What is the ticker symbol for Halozyme Therapeutics, Inc.?

The ticker symbol for Halozyme Therapeutics, Inc. is NASDAQ:HALO

Does Halozyme Therapeutics, Inc. pay dividends?

No, Halozyme Therapeutics, Inc. does not pay dividends

What sector is Halozyme Therapeutics, Inc. in?

Halozyme Therapeutics, Inc. is in the Healthcare sector

What industry is Halozyme Therapeutics, Inc. in?

Halozyme Therapeutics, Inc. is in the Biotechnology industry

What country is Halozyme Therapeutics, Inc. based in?

Halozyme Therapeutics, Inc. is headquartered in United States

When did Halozyme Therapeutics, Inc. go public?

Halozyme Therapeutics, Inc. initial public offering (IPO) was on March 16, 2004

Is Halozyme Therapeutics, Inc. in the S&P 500?

No, Halozyme Therapeutics, Inc. is not included in the S&P 500 index

Is Halozyme Therapeutics, Inc. in the NASDAQ 100?

No, Halozyme Therapeutics, Inc. is not included in the NASDAQ 100 index

Is Halozyme Therapeutics, Inc. in the Dow Jones?

No, Halozyme Therapeutics, Inc. is not included in the Dow Jones index

When was Halozyme Therapeutics, Inc. last earnings report?

Halozyme Therapeutics, Inc.'s most recent earnings report was on August 6, 2026

When does Halozyme Therapeutics, Inc. report earnings?

The next expected earnings date for Halozyme Therapeutics, Inc. is November 2, 2026

HALO Stock Financials, Chart, Sentiment & Profile

Summary

Current Price: As of today, HALO price is $121.84, up +0.27% on October 16, 2026
Current Price All-Time High: HALO price is currently -0.49% below its historical high of $122.45 set on October 16, 2026
Market Cap: HALO current market cap is $14B, up +75.94% over the past 365 days
PE Ratio: HALO current PE ratio is 36.40
Revenue: HALO current annual revenue is $1.40B, up +37.55% year-over-year
Next Earnings: The next earnings release for HALO is on November 2, 2026

Profile

Company profile for Halozyme Therapeutics, Inc. (HALO)
Metric	Value
Full Name	Halozyme Therapeutics, Inc.
Ticker	NASDAQ: HALO
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology
Country	United States
IPO	Mar 16, 2004
Indexes	Not included
Website	halozyme.com
Employees	350

Key Metrics

Halozyme Therapeutics, Inc. Key Details
Metric	Value	Date
Price	$121.84	Oct 16, 26
Price, 1D Change	+0.27%	Oct 16, 26
Market Cap	$14B	Oct 16, 26
	-	Oct 16, 26
PE Ratio	36.40	Oct 16, 26
Beta	0.48	Oct 16, 26
Revenue	$1.40B	Dec 31, 25
Revenue, 1Y Change	+37.55%	Dec 31, 25
EPS	$2.56	Dec 31, 25
EPS, 1Y Change	-25.47%	Dec 31, 25

Events

Halozyme Therapeutics, Inc. Events
Metric	Value	Date
Next Earnings		Nov 2, 26
Last Qtr. Earnings		Aug 6, 26
Last Ann. Earnings		Feb 17, 26
Last Ex-Dividend	N/A	N/A
Next Ex-Dividend	N/A	N/A
Last Split	N/A	N/A
Next Split	N/A	N/A
Last Ticker Change	HTI	Apr 30, 07
Next Ticker Change	N/A	N/A

🔒 Log In To Unlock Full Data

Estimates

HALO Estimates
Metric	Value	Date
EPS	$2.56	Dec 31, 25
EPS Estimate	$8.71	N/A
EPS Est. Change	+240.72%	N/A
Revenue	$1.40B	Dec 31, 25
Revenue Estimate	$1.87B	N/A
Revenue Est. Change	+33.93%	N/A
Current Price	$121.84	Oct 16, 26
Price Target	$100.00	-
Price Tgt. Change	-17.93%	-

🔒 Log In To Unlock Full Data

EPS

HALO EPS reported versus estimate values
Year	Estimate	Reported	Surprise / Exp.
2024	$4.13	$3.43	-16.87%
2025	$6.55	$2.56	-60.98%
2026	$8.71	N/A	+240.72%
2027	$10.63	N/A	+315.74%

Revenue

HALO revenue reported versus estimate values chart
Year	Estimate	Reported	Surprise / Exp.
2024	$1.00B	$1.02B	+1.21%
2025	$1.39B	$1.40B	+0.21%
2026	$1.87B	N/A	+33.93%
2027	$2.07B	N/A	+48.32%

🔒 Log In To Unlock Full Data

Performance

HALO Performance
Metric	Value	Date
Price, 1Y	+82.18%	Oct 16, 26
Price, 3Y	+229.21%	Oct 16, 26
Market Cap, 1Y	+75.94%	Oct 16, 26
Market Cap, 3Y	+182.89%	Oct 16, 26
Revenue, 1Y	+37.55%	Dec 31, 25
Revenue, 3Y	+111.57%	Dec 31, 25
EPS, 1Y	-25.47%	Dec 31, 25
EPS, 3Y	+77.91%	Dec 31, 25

🔒 Log In To Unlock Full Data

Technicals

HALO Technical Indicators
Metric	Value	Date
Current Price	$121.84	Oct 16, 26
SMA 200	$80.61	Oct 16, 26
SMA 50	$108.92	Oct 16, 26
EMA 200	$85.79	Oct 16, 26
EMA 50	$106.19	Oct 16, 26
MACD	$2.78	Oct 16, 26
Beta	0.48	Oct 16, 26
ATR	$3.61	Oct 16, 26
14-Day RSI	70.34	Oct 16, 26
10-Day Volatility	39.47%	Oct 16, 26

Dividends

HALO Dividends
Metric	Value	Date
	-	N/A
Upcoming	N/A	N/A
	-	Oct 16, 26
	-	Dec 31, 25
	$0.00	Dec 31, 25
	0.00%	Dec 31, 25

🔒 Log In To Unlock Full Data

Income & Profitability

HALO Income & Profitability
Metric	Value	Date
Revenue	$1.40B	Dec 31, 25
EPS	$2.56	Dec 31, 25
Gross Profit	$1.09B	Dec 31, 25
Gross Margin	78.13%	Dec 31, 25
Operating Income	$816.29M	Dec 31, 25
Operating Margin	58.45%	Dec 31, 25
Net Income	$316.89M	Dec 31, 25
Net Margin	22.69%	Dec 31, 25
EBITDA	$904.34M	Dec 31, 25

🔒 Log In To Unlock Full Data

Financial Health

HALO Financial Health
Metric	Value	Date
Debt To Equity	44.60	Dec 31, 25
	4.66	Dec 31, 25
	3.66	Dec 31, 25
	-	Dec 31, 25
	5	Jun 30, 26
	4.93	Oct 16, 26

Valuations

HALO Valuations
Metric	Value	Date
PE Ratio	36.40	Oct 16, 26
	8.31	Oct 16, 26
	96.34	Oct 16, 26
	14.86	Oct 16, 26
	-	N/A

Balance Sheet

HALO Balance Sheet
Metric	Value	Date
Book Value	$48.81M	Dec 31, 25
	$142.82M	Dec 31, 25
	$2.71B	Dec 31, 25
	$825.21M	Dec 31, 25
	$2.67B	Dec 31, 25
	$177.09M	Dec 31, 25
Total Debt	$2.18B	Dec 31, 25
	$11.28M	Dec 31, 25
	$20.90M	Dec 31, 25

Expenses

HALO Expenses
Metric	Value	Date
	$1.08B	Dec 31, 25
	$274.88M	Dec 31, 25
	$305.44M	Dec 31, 25
	$0.00	Dec 31, 25
	$88.05M	Dec 31, 25
	$0.00	Dec 31, 25
	$149.99M	Dec 31, 25

Cash Flow

HALO Cash Flow
Metric	Value	Date
	$651.56M	Dec 31, 25
	-$545.81M	Dec 31, 25
	-$85.17M	Dec 31, 25
Capex	$6.97M	Dec 31, 25
	$644.59M	Dec 31, 25

Recent analyst updates

HALO Recent analyst updates
Metric	Value	Date
JP Morgan	→	Oct 8, 26
HC Wainwright & Co.	→	Oct 8, 26
HC Wainwright & Co.	→	Sep 2, 26
Leerink Partners	→	Aug 8, 26
Wells Fargo	→	Aug 7, 26
TD Cowen	→	Aug 7, 26
HC Wainwright & Co.	→	Aug 7, 26
Citizens	→	Aug 7, 26
HC Wainwright & Co.	→	Jul 21, 26
Morgan Stanley	→	May 12, 26

Analyst sentiment

Institutional ownership

Screeners with HALO

FAQ

What is the ticker symbol for Halozyme Therapeutics, Inc.?: The ticker symbol for Halozyme Therapeutics, Inc. is NASDAQ:HALO
Does Halozyme Therapeutics, Inc. pay dividends?: No, Halozyme Therapeutics, Inc. does not pay dividends
What sector is Halozyme Therapeutics, Inc. in?: Halozyme Therapeutics, Inc. is in the Healthcare sector
What industry is Halozyme Therapeutics, Inc. in?: Halozyme Therapeutics, Inc. is in the Biotechnology industry
What country is Halozyme Therapeutics, Inc. based in?: Halozyme Therapeutics, Inc. is headquartered in United States
When did Halozyme Therapeutics, Inc. go public?: Halozyme Therapeutics, Inc. initial public offering (IPO) was on March 16, 2004
Is Halozyme Therapeutics, Inc. in the S&P 500?: No, Halozyme Therapeutics, Inc. is not included in the S&P 500 index
Is Halozyme Therapeutics, Inc. in the NASDAQ 100?: No, Halozyme Therapeutics, Inc. is not included in the NASDAQ 100 index
Is Halozyme Therapeutics, Inc. in the Dow Jones?: No, Halozyme Therapeutics, Inc. is not included in the Dow Jones index
When was Halozyme Therapeutics, Inc. last earnings report?: Halozyme Therapeutics, Inc.'s most recent earnings report was on August 6, 2026
When does Halozyme Therapeutics, Inc. report earnings?: The next expected earnings date for Halozyme Therapeutics, Inc. is November 2, 2026

Data Sources & References

HALO Official Website halozyme.com
Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1159036/000115903626000024/0001159036-26-000024-index.htm
HALO Profile on Yahoo Finance finance.yahoo.com/quote/HALO
HALO Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/halo